GENE logo

Genetic Technologies Ltd.


GENE: Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.


Show GENE Financials

Consumer Interest
SEC Filings

Recent trades of GENE by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by GENE's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods of assessing risk of developing a severe response to coronavirus infection Feb. 22, 2022
  • Patent Title: Methods for breast cancer risk assessment Jul. 27, 2021
  • Patent Title: Computer systems and methods for genomic analysis Jun. 08, 2021
  • Patent Title: Method for modifying a treatment regimen of a human female subject Feb. 16, 2021
  • Patent Title: Methods for assessing risk of developing breast cancer Jun. 16, 2020
  • Patent Title: Methods for obtaining fetal genetic material Sep. 20, 2016
  • Patent Title: Biological sampling device Jul. 14, 2015
  • Patent Title: Biological sampling device Sep. 09, 2014
  • Patent Title: Device and method for obtaining a biological sample May. 27, 2014
  • Patent Title: Identification of fetal dna and fetal cell markers in maternal plasma or serum Mar. 12, 2013
  • Patent Title: Methods of genetic analysis involving the amplification of complementary duplicons Nov. 20, 2012
  • Patent Title: Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood Aug. 31, 2010

Number of mentions of GENE in WallStreetBets Daily Discussion


Recent insights relating to GENE

CNBC Recommendations

Recent picks made for GENE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in GENE

Corporate Flights

Flights by private jets registered to GENE